HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells.

Abstract
Elucidation of the mechanisms responsible for aberrant phosphatidylcholine (PC) metabolism in cancer cells may allow identification of novel biomarkers of tumor progression and design of new targeted anticancer therapies. We recently reported up-regulation of PC-specific phospholipases in epithelial ovarian cancer cells (EOC) compared with nontumoral (normal or immortalized) counterparts (EONT). In the present study, we focused, in the same cell systems, on levels, subcellular localization, and activity of PC-specific phospholipase C (PC-PLC), for which a key role in cell proliferation, differentiation, and apoptosis has been shown in several mammalian cells. A 66-kDa PC-PLC isoform, detected in nuclear and cytoplasmic compartments of both EOC and EONT cells, accumulated on the external plasma membrane of cancer cells only, where it colocalized with beta1 integrin, in nonraft membrane domains. PC-PLC activity was 3-fold higher in total cell lysates and 5-fold higher in membrane-enriched fractions of EOC compared with EONT cells. Serum deprivation induced in EOC, but not in EONT, cells a 3-fold decrease in PC-PLC activity, associated with a 40% drop in S-phase fraction. The recovery of both variables to their original levels in serum-restimulated (or lysophosphatidic acid-restimulated) EOC cells was strongly delayed, for at least 24 h, in the presence of the PC-PLC inhibitor tricyclodecan-9-yl-potassium xanthate (D609). The S-phase of serum-restimulated EONT cells was not sensitive to D609. These findings warrant further investigations on the role of PC-PLC and on the effects of its inhibition on the pathways responsible for constitutive EOC cell stimulation and cell proliferation.
AuthorsFrancesca Spadaro, Carlo Ramoni, Delia Mezzanzanica, Silvia Miotti, Paola Alberti, Serena Cecchetti, Egidio Iorio, Vincenza Dolo, Silvana Canevari, Franca Podo
JournalCancer research (Cancer Res) Vol. 68 Issue 16 Pg. 6541-9 (Aug 15 2008) ISSN: 1538-7445 [Electronic] United States
PMID18701477 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Bridged-Ring Compounds
  • Culture Media, Serum-Free
  • Norbornanes
  • Phosphodiesterase Inhibitors
  • Thiocarbamates
  • Thiones
  • tricyclodecane-9-yl-xanthogenate
  • TERT protein, human
  • Telomerase
  • Type C Phospholipases
  • phosphatidylcholine-specific phospholipase C
  • Phospholipase D
Topics
  • Adenocarcinoma, Clear Cell (enzymology, secondary)
  • Adenocarcinoma, Mucinous (enzymology, secondary)
  • Apoptosis (physiology)
  • Bridged-Ring Compounds (pharmacology)
  • Carcinoma, Endometrioid (enzymology, secondary)
  • Cell Membrane (enzymology, pathology)
  • Cell Nucleus (enzymology, pathology)
  • Culture Media, Serum-Free (pharmacology)
  • Cystadenocarcinoma, Serous (enzymology, secondary)
  • Cytoplasm (enzymology, pathology)
  • Enzyme Activation
  • Epithelium (enzymology, pathology)
  • Female
  • Flow Cytometry
  • Humans
  • Membrane Microdomains
  • Norbornanes
  • Ovarian Neoplasms (enzymology, pathology)
  • Ovary (enzymology, pathology)
  • Phosphodiesterase Inhibitors (pharmacology)
  • Phospholipase D (metabolism)
  • S Phase (physiology)
  • Telomerase (metabolism)
  • Thiocarbamates
  • Thiones (pharmacology)
  • Type C Phospholipases (antagonists & inhibitors, genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: